{"id":"32da6952def0","type":"article","url":"https://hartvaat.nl/2026/03/31/mr-proadm-voorspelt-mortaliteit-en-hf-events-bij-attr-cardiale-amyloidose/","title":"MR-proADM voorspelt mortaliteit en HF-events bij ATTR cardiale amyloïdose","title_en":"","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["biomarkers-cardiovasculair","cardiale-amyloidose","nt-probnp","troponine"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077833","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077833","authors":["Belén Peiró"],"significance":7,"published":"2026-04-26","source_date":"2026-03-31","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/","https://hartvaat.nl/kennis/coronairlijden/troponine-interpretatie/"],"congress":"","summary_en":"In 337 ATTR-CM patients from Spain, 12 circulating biomarkers were benchmarked for predicting mortality and HF events, with validation in two independent cohorts. Mid-regional pro-adrenomedullin (MR-proADM) emerged as a robust complement to NT-proBNP and high-sensitivity troponin for risk stratification — increasingly relevant as ATTR cardiomyopathy is diagnosed earlier and new therapies improve prognosis.","created":"2026-07-03T10:32:48Z","updated":"2026-07-03T13:31:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In 337 ATTR-CM-patiënten uit Spanje werden 12 circulerende biomarkers vergeleken als voorspellers van mortaliteit en hartfalen-events, gevalideerd in twee onafhankelijke cohorten. Mid-regional pro-adrenomedulline (MR-proADM) kwam naar voren als robuuste aanvulling op NT-proBNP en hoog-sensitief troponine voor risicoclassificatie — relevant nu ATTR-amyloïdose eerder wordt gediagnosticeerd en nieuwe therapieën (tafamidis, vutrisiran) de prognose doen verbeteren.","abstract_original":"BACKGROUND:With the increasing diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) at earlier stages and new therapies, there is a rising demand for tools to stratify risk and prognosis. We evaluated the prognostic value of multiple circulating biomarkers for predicting outcomes in ATTR-CM.METHODS:We evaluated 12 different circulating biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP], high-sensitivity troponin I [hsTnI], mid-regional pro-adrenomedullin [MR-proADM], carbohydrate antigen 125 [CA125], soluble suppressor of tumorigenicity 2 [sST2], cluster of differentiation antigen 146 [CD146], growth/differentiation factor-15 [GDF-15], alpha-klotho, fibroblast growth factor 23 [FGF-23], galectin-3, insulin-like growth factor-binding protein 7 [IGFBP-7], and estimated glomerular filtration rate [eGFR]) in 337 ATTR-CM patients from Spain. Cox models were employed to determine their predictive abilities. Findings were validated in 2 independent external cohorts of 21"}